Direct answer
Reproduce101 maps the technologies, companies, and markets reshaping reproduction and fertility.
The focus is AI-enabled reproduction: fertility, surrogacy, maternal-fetal risk, embryo technologies, reproductive genetics, and the infrastructure layer forming around them. It points readers to the Reproduce101 Substack for essays and deeper field notes.
At the securities exchange, I worked on IPOs for biotech and technology companies. Later, a few co-founder attempts, including one company that reached unicorn valuation, pulled me toward a different question: how markets open, how products change behavior, and how new demand gets created.
Today I'm building an AI-enabled reproduction and fertility company, starting with surrogacy and maternal risk prediction across Thailand, the U.S., and South Korea.
My broader interests are fertility, surrogacy, embryo technologies, reproductive genetics, and maternal-fetal risk. The thesis is simple: AI can remove friction from human reproduction and expand what people can do.
Friction is the wedge. When complex, expensive workflows become simple and natural, behavior changes. New demand shows up. New markets form.
Still an outsider to biology, I'm learning fast. This site is where I write that learning in public: reproduction, fertility, AI, and the technologies and companies shaping the next generation of reproduction and fertility startups.